Esketamine Compound Development Team Leader
Dave is currently the Esketamine Compound Development Team Leader (CDTL) where he is leading the global development of SPRAVATO (esketamine) nasal spray for two indications: treatment resistant depression (TRD) and major depression in patients with imminent suicidality. He is responsible for all the clinical, medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program. Esketamine is also being developed in pediatric patients 12-17 years old who have major depression with imminent suicidality. Dave was previously the Schizophrenia Disease Area Research & Development Leader and was responsible for the execution of an end-to-end strategy for development of medications and solutions to treat schizophrenia. He was also the Paliperidone CDTL responsible for the adult and pediatric development programs including oral INVEGA, INVEGA SUSTENNA/XEPLION 1 month, and INVEGA TRINZA/TREVECTA. Dave is a graduate of West Point and served for several years as a regular Army officer before attending medical school at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. After completing residency training in Psychiatry at Walter Reed Medical Center in Washington DC, he served for 10 years as an Army psychiatrist at two separate community hospitals and on faculty at a psychiatry residency program in Honolulu, Hawaii. He supervised numerous psychiatry residents and allied mental health professionals serving as head of outpatient clinics and behavioral health departments. He completed a two-year research fellowship in Clinical Pharmacology jointly sponsored by USUHS and Walter Reed Army Institute of Research. He is board certified in both Adult and Geriatric Psychiatry and held an Adjunct Assistant Professor of Psychiatry position at USUHS for several years. He has authored numerous publications in peer reviewed journals, is a reviewer for several journals, and was an examiner for the American Board of Psychiatry and Neurology.
None yet.